Medical Hypotheses
Volume 56, Issue 1 , Pages 12-16 , January 2001

Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation

Received 24 November 1999 ,Accepted 6 January 2000.

References 

    REFERENCES
  1. Doyle JW, Kandutsch AA. Requirement for mevalonate in cycling cells: quantitative and temporal aspects. J Cell Physiol. 1988;137:133–140
  2. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA. 1991;88:3628–3632
  3. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991;51:3602–3609
  4. Langan TJ, Slater MC. Isoprenoids and astroglial cell cycling: diminished mevalonate availability and inhibition of dolichol-linked glycoprotein synthesis arrest cycling through distinct mechanisms. J Cell Physiol. 1991;149:284–292
  5. Larsson O. Cell cycle-specific growth inhibition of human breast cancer cells induced by metabolic inhibitors. Glycobiology. 1993;3:475–479
  6. Naderi S, Blomhoff R, Myklebust J. Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis. Exp Cell Res. 1999;252:144–153
  7. Carlberg M, Dricu A, Blegen H. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J Biol Chem. 1996;271:17453–17462
  8. Ishii S, Volpe JJ. Dolichol-linked glycoprotein synthesis in G1 is necessary for DNA synthesis in synchronized primary cultures of cerebral glia. J Neurochem. 1987;49:1606–1612
  9. Kabakoff BD, Doyle JW, Kandutsch AA. Relationships among dolichyl phosphate, glycoprotein synthesis, and cell culture growth. Arch Biochem Biophys. 1990;276:382–389
  10. Dricu A, Wang M, Hjertman M. Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-IR) in comparison to Ras prenylation and expressionof c- myc. Glycobiology. 1997;7:625–633
  11. Dricu A, Carlberg M, Wang M, Larsson O. Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis. Cancer Res. 1997;57:543–548
  12. Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest. 1995;73:311–331
  13. Qian Y, Sebti SM, Hamilton AD. Farnesyltransferase as a target for anticancer drug design. Biopolymers. 1997;43:25–41
  14. Kelloff GJ, Lubet RA, Fay JR. Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1997;6:267–282
  15. Carboni JM, Yan N, Cox AD. Farnesyltransferase inhibitors are inhibitors of Ras but not R- Ras2/TC21, transformation. Oncogene. 1995;10:1905–1913
  16. Elson CE, Peffley DM, Hentosh P, Mo H. Isoprenoid-mediated inhibition of mevalonate synthesis: potential,application to cancer. Proc Soc Exp Biol Med. 1999;221:294–311
  17. Karlson J, Borg-Karlson AK, Unelius R. Inhibition of tumor cell growth by monoterpenes in vitro: evidence of a Ras-independent mechanism of action. Anticancer Drugs. 1996;7:422–429
  18. Ren Z, Elson CE, Gould MN. Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem Pharmacol. 1997;54:113–120
  19. Hardcastle IR, Rowlands MG, Barber AM. Inhibition of protein prenylation by metabolites of limonene. Biochem Pharmacol. 1999;57:801–809
  20. Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem. 1997;272:27224–27229
  21. Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem. 1996;271:5289–5292
  22. Sebti SM, Hamilton AD. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol Ther. 1997;74:103–114
  23. He L, Mo H, Hadisusilo S, Qureshi AA, Elson CE. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr. 1997;127:668–674
  24. Elson CE. Suppression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer and cardiovascular disease. J Nutr. 1995;125:1666S–1672S
  25. Case GL, He L, Mo H, Elson CE. Induction of geranyl pyrophosphate pyrophosphatase activity by cholesterol- suppressive isoprenoids. Lipids. 1995;30:357–359
  26. Elson CE, Yu SG. The chemoprevention of cancer by mevalonate-derived constituents of fruits and vegetables. J Nutr. 1994;124:607–614
  27. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3- hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1993;268:11230–11238
  28. Harrison LE, Wojciechowicz DC, Brennan MF, Paty PB. Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma. Surgery. 1998;124:541–550
  29. Nagourney RA. Oral limonene: combined prenylation inhibitor therapy of cancer. J Medicinal Food. 1998;1:83–88
  30. Levy J, Bosin E, Feldman B. Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. Nutr Cancer. 1995;24:257–266
  31. Fuhrman B, Elis A, Aviram M. Hypocholesterolemic effect of lycopene and beta-carotene is related to suppression of cholesterol synthesis and augmentation of LDL receptor activity in macrophages. Biochem Biophys Res Commun. 1997;233:658–662
  32. Narisawa T, Fukaura Y, Hasebe M. Prevention of N-methylnitrosourea-induced colon carcinogenesis in F344 rats by lycopene and tomato juice rich in lycopene. Jpn J Cancer Res. 1998;89:1003–1008
  33. Okajima E, Tsutsumi M, Ozono S. Inhibitory effect of tomato juice on rat urinary bladder carcinogenesis after N-butyl-N-(4-hydroxybutyl)nitrosamine initiation. Jpn J Cancer Res. 1998;89:22–26
  34. Sharoni Y, Giron E, Rise M, Levy J. Effects of lycopene-enriched tomato oleoresin on 7,12-dimethyl- benz[a]anthracene-induced rat mammary tumors. Cancer Detect Prev. 1997;21:118–123
  35. Narisawa T, Fukaura Y, Hasebe M. Prevention of N-methylnitrosourea-induced colon carcinogenesis in F344 rats by lycopene and tomato juice rich in lycopene. Jpn J Cancer Res. 1998;89:1003–1008
  36. Okajima E, Tsutsumi M, Ozono S. Inhibitory effect of tomato juice on rat urinary bladder carcinogenesis after N-butyl-N-(4-hydroxybutyl)nitrosamine initiation. Jpn J Cancer Res. 1998;89:22–26
  37. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst. 1999;91:317–331
  38. Dricu A, Kanter L, Wang M. Expression of the insulin-like growth factor 1 receptor (IGF-IR) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an intracellular to an extracellular IGF-I pathway. Glycobiology. 1999;9:571–579
  39. Tricoli JV, Winter DL, Hanlon AL. Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology. 1999;54:178–182
  40. Wolk A, Mantzoros CS, Andersson SO. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study [see comments]. J Natl Cancer Inst. 1998;90:911–915
  41. Chan JM, Stampfer MJ, Giovannucci E. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study [see comments]. Science. 1998;279:563–566
  42. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia [see comments]. Br J Cancer. 1997;76:1115–1118
  43. Stoll BA. Western nutrition and the insulin resistance syndrome: a link to breast cancer. Eur J Clin Nutr. 1999;53:83–87
  44. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology. 1998;9:570–573
  45. Hankinson SE, Willett WC, Colditz GA. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer [see comments]. Lancet. 1998;351:1393–1396
  46. Ng EH, Ji CY, Tan PH, Lin V, Soo KC, Lee KO. Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients. Ann Surg Oncol. 1998;5:194–201
  47. Kazer RR. Insulin resistance, insulin-like growth factor I and breast cancer: a hypothesis. Int J Cancer. 1995;62:403–406
  48. Manousos O, Souglakos J, Bosetti C. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer. 1999;83:15–17
  49. McCarty MF. Up-regulation of IGF binding protein-1 as an anticarcinogenic strategy: relevance to caloric restriction, exercise, and insulin sensitivity. Med Hypotheses. 1997;48:297–308
  50. McCarty MF. Vegan proteins may reduce risk for cancer, obesity, and cardiovascular disease by promoting increased glucagon activity. Med Hypotheses. 1999;53:459–485
  51. McCarty MF. Dietary glycemic index may influence cancer risk by modulating IGF-I activity: a hypothesis. J Medicinal Food. 1998;1:123–140
  52. Holly J. Insulin-like growth factor-I and new opportunities for cancer prevention [comment]. Lancet. 1998;351:1373–1375
  53. Ruggeri BA, Klurfeld DM, Kritchevsky D, Furlanetto RW. Caloric restriction and 7,12- dimethylbenz(a)anthracene-induced mammary tumor growth in rats: alterations in circulating insulin, insulin-like growth factors I and II, and epidermal growth factor. Cancer Res. 1989;49:4130–4134
  54. Dunn SE, Kari FW, French J. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 1997;57:4667–4672
  55. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr. 1999;129:1628–1635
  56. Campagnoli C, Biglia N, Peris C, Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol. 1995;9:67–74
  57. Helle SI, Omsjo IH, Hughes SC. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol (Oxf). 1996;45:727–732
  58. Lonning PE, Hall K, Aakvaag A, Lien EA. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res. 1992;52:4719–4723
  59. Lahti EI, Knip M, Laatikainen TJ. Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer. 1994;74:618–624
  60. Helle SI, Holly JM, Tally M, Hall K, Vander SJ, Lonning PE. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer. 1996;69:335–339
  61. Bohannon NJ, Corp ES, Wilcox BJ, Figlewicz DP, Dorsa DM, Baskin DG. Characterization of insulin-like growth factor I receptors in the median eminence of the brain and their modulation by food restriction. Endocrinology. 1988;122:1940–1947
  62. Eshet R, Werner H, Klinger B. Up-regulation of insulin-like growth factor-I (IGF-I) receptor gene expression in patients with reduced serum IGF-I levels. J Mol Endocrinol. 1993;10:115–120
  63. Hernandez-Sanchez C, Werner H, Roberts CIJ. Differential regulation of insulin-like growth factor-I (IGF-I) receptor gene expression by IGF-I and basic fibroblastic growth factor. J Biol Chem. 1997;272:4663–4670
  64. Smith LE, Kopchick JJ, Chen W. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276:1706–1709
  65. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia. 1993;36:282–291
  66. Nicosia RF, Nicosia SV, Smith M. Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol. 1994;145:1023–1029
  67. Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression [see comments]. J Natl Cancer Inst. 1999;91:512–523
  68. Zhou JR, Gugger ET, Tanaka T, Guo Y, Blackburn GL, Clinton SK. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J Nutr. 1999;129:1628–1635
  69. Nakao-Hayashi J, Ito H, Kanayasu T, Morita I, Murota S. Stimulatory effects of insulin and insulin-like growth factor I on migration and tube formation by vascular endothelial cells. Atherosclerosis. 1992;92:141–149
  70. Goad DL, Rubin J, Wang H, Tashjian AHJ, Patterson C. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology. 1996;137:2262–2268
  71. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem. 1996;271:29483–29488
  72. Punglia RS, Lu M, Hsu J. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 1997;46:1619–1626
  73. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res. 1998;58:4008–4014
  74. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J. 1998;17:5085–5094
  75. Banerjee DK, Vendrell-Ramos M. Is asparagine-linked protein glycosylation an obligatory requirement for angiogenesis?. Indian J Biochem Biophys. 1993;30:389–394
  76. Banerjee DK. Angiogenesis: characterization of a cellular model. P R Health Sci J. 1998;17:327–333
  77. Martinez JA, Torres-Negron I, Amigo LA, Banerjee DK. Expression of Glc3Man9GlcNAc2-PP-Dol is a prerequisite for capillary endothelial cell proliferation. Cell Mol Biol (Noisy-le-grand). 1999;45:137–152
  78. Feleszko W, Balkowiec EZ, Sieberth E. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer. 1999;81:560–567

PII: S0306-9877(00)91073-9

doi: 10.1054/mehy.2000.1073

Medical Hypotheses
Volume 56, Issue 1 , Pages 12-16 , January 2001

Article Tools